Biogen and UCB present positive Phase 3 PHOENYCS GO data for lupus candidate dapirolizumab pegol
Biogen (NASDAQ:BIIB) and UCB have announced the release of positive results from the Phase 3 PHOENYCS GO clinical trial evaluating dapirolizumab pegol (DZP), an investigational treatment for systemic lupus erythematosus (SLE).


-640x360.webp&w=3840&q=75)







